News

InSysBio has recently launched weekly series on YouTube about the Heta language. Heta is a modeling language for quantitative systems pharmacology and systems biology. Now InSysBio presents the tutorial consisting of short lessons that familiarize with Heta, describe its features and show examples.

CYTOCON DB Open is designed for free public use [Moscow – 12.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has extended the variety of options to experience its CYTOCON DB with a new way. In general, the database allows to investigate the concentration of multiple species measured in different tissues of patients. Now InSysBio presents its public version entitled “CYTOCON DB Open”.

[Moscow – 10.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new access mode to Immune Response Template (IRT) version 3. Now any modeler can experience or get acquainted with IRT via Demo access without the necessity to purchase the license.

Latest news about Cytocon DB! Its new version 1.3.6.8 got a number of principal update

DBSolveOptimum 2020 provides extended opportunities for QSP modeling [Moscow, Russia – 06.10.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases the new version of mathematical simulation workbench DBSolveOptimum 2020. It represents a significantly advanced and extended successor of the well-known simulation software DBSolveOptimum described in the paper [PMID 20698988] published in 2010. DBSolve is a user friendly simulation software package that enables to simplify the development, calibration and analysis of QSP models.

The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB) [Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.